AlphAIAlphAI — Financial news for AI agents
Zacks CommentarySEP 24 min read$ATNM

Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?

Here is how Actinium Pharmaceuticals (ATNM) and Avadel (AVDL) have performed compared to their sector so far this year.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Sep 2, 2025, 1:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? — source image
Source · www.zacks.com
Decision brief

The 30-second read

$ATNMBullishMed
01

Why it matters

This performance may attract short-term trading interest, but underlying fundamentals should be verified.

02

Market read

The article highlights sector-specific performance, relevant for traders focusing on biotech stocks.

03

What to watch

Potential regulatory or clinical trial developments could alter outlook.

Relevance 6/10Timing: short-term

Background

Actinium Pharmaceuticals has recently demonstrated relative performance gains within the biotech sector, possibly driven by positive clinical news or investor sentiment.

Company-level read

Ticker impact

$ATNMBullishMedium confidence
Context

Actinium Pharmaceuticals (ATNM) is a biotech company with recent performance compared to peers.

Expected impact

Moderate upward movement expected in the short term.

Evidence & confidence

Recent relative outperformance suggests increased investor confidence, but lack of detailed technical data limits certainty.

Market effects

Sector

Positive sentiment in biotech sector; potential spillover effects on related stocks.

Regional

Primarily US-focused, limited global impact.

Global

Low; sector-specific news.

Counterpoint

What could challenge this read

Sector outperformance may be temporary; fundamentals of ATNM need further validation.

Key entities

  • Company
    Actinium Pharmaceuticals

    Biotech firm focused on targeted radiotherapies.

  • Company
    Avadel

    Pharmaceutical company specializing in sleep and neurological therapies.

Read at source← All news

Related articles

OCT 15
$ATNMMedAI 8/10

Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

Actinium Pharmaceuticals (ATNM) announced early Phase 1 trial results for ATNM-400, a non-PSMA targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC), to be presented at EANM 2026. The study assesses safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400, aiming to inform therapeutic dosing with Actinium-225-labeled ATNM-400.

prnewswire.com2 min
OCT 15
$ATNMMedAI 8/10

Some prostate cancers progress after targeted therapy. Actinium is testing radiation aimed at a different target.

Actinium Pharmaceuticals presented early Phase 1 trial data for ATNM-400, a non-PSMA targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC). The study aims to assess safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400, with plans to advance to Actinium-225-labeled therapy. According to the company, ATNM-400 targets a novel antigen and could benefit a broad mCRPC patient population, including those resistant to PSMA-directed therapies.

stocktitan.net2 min
AUG 14
$ATNMMed

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

Actinium Pharmaceuticals (NYSE American: ATNM) said it expanded Actimab-A intellectual property with multiple newly issued US patents and additional pre-grant/allowed applications, covering uses in AML, MDS, and solid tumors, including combinations with venetoclax and CLAG-M. The company also amended its IND to add a manufacturing source and reported NYSE American listing compliance plan acceptance through Nov. 27, 2027.

prnewswire.com4 min
MAY 29
$ATNMLow

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

Actinium Pharmaceuticals said the Canadian Intellectual Property Office issued Notices of Allowance for two patent applications covering its Actimab-A and Iomab-ACT programs. The Actimab-A/CLAG-M AML combination allowance is expected to issue with a term into Jan. 2039; the CD45 conditioning for gene-edited cell therapies is expected to issue with a term into Oct. 2038. Actinium said this adds to a global portfolio of about 250 issued and pending patents.

prnewswire.com3 min
MAY 29
$ATNMMedAI 9/10

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

Actinium Pharmaceuticals (NYSE American: ATNM) said it will present new ATNM-400 (Actinium-225 antibody radioconjugate) data at SNMMI 2026 in Los Angeles May 30–June 2, with three posters on prostate cancer, NSCLC, and radioconjugate optimization. Separately, NYSE American notified the company it is not in compliance with $4.0m stockholders’ equity requirements; Actinium must submit a compliance plan by June 26, 2026.

prnewswire.com4 min
OCT 15
$NFLXMed

Bela Bajaria Is Out at Netflix, Peter Rice Is In

Netflix announced Bela Bajaria is stepping down as Chief Content Officer, replaced by Peter Rice. Ted Sarandos praised her decade of service. This follows Netflix's recent layoffs of 1,000 employees. Bajaria led content expansion, including unscripted programming and live events.

vulture.com2 min